Second Irregularity In NSABP Data Found; Fisher Takes Leave As Group’s Chairman
In Brief: Ross Retires From Bristol-Myers, Forms Own Consulting Service; Obey Wins Key Post
NCI Promises Strong Monitoring Process Visco Calls For Independent Review; Rep. Dingell Plans Hearing April 13
Biotech Organization Endorses Measures On Orphan Drug Act
Salick Signs contract for Fixed-Price Oncology Services
DCE Advisors OK RFAs In Occupational Cancer, H. Pylori
Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- Peter F. Garrett to people with cancer: Your story has power
- What NHS-Galleri taught us—and what it didn’t
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”









